Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.64 |
| ▸ | DRD2 | P14416 | 5/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7525519 | 0.94 | HTR1A (0.66) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| Bromide SCHEMBL7524714 | 0.93 | HTR1A (0.64) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| SCHEMBL14761427 | 0.93 | HTR1A (0.66) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| SCHEMBL14761630 | 0.92 | HTR1A (0.67) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| Fumaric Acid SCHEMBL7522937 | 0.92 | HTR1A (0.55) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| Fumaric Acid SCHEMBL7522943 | 0.92 | HTR1A (0.55) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| SCHEMBL7529659 | 0.89 | HTR1A (0.57) | HTR1ADRD2ADRA1ADRD3 | |
| SCHEMBL7528032 | 0.88 | HTR1A (0.58) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| Bromide SCHEMBL7526628 | 0.88 | HTR1A (0.57) | HTR1ADRD2ADRA1ADRD3HTR2A | |
| SCHEMBL7526732 | 0.86 | BCHE (0.58) | HTR1ADRD2ADRA1AHTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | claimed |
| CN-1325397-A | 2-piperazino alkylatnino benzoazole derivatives: dopamine receptor subtype sepcific ligands | NEUROGEN CORP (US) | 2001-12-05 | — | — | CN | claimed |
| EP-1117663-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018767-A9 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2001-04-19 | — | — | WO | claimed |
| WO-2000018767-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-06 | — | — | WO | claimed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011150183-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | GE HEALTHCARE LIMITED (GB) | 2011-12-01 | — | — | WO | disclosed |
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
| EP-1117663-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018767-A9 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000018767-A2 | 2-PIPERAZINO ALKYLAMINO BENZOAZOLE DERIVATIVES: DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064770-A1 | RADIOLABELED COMPOUNDS AND METHODS THEREOF | HTR5A, HTR3B, HTR1A | HTR1A 3/4885DRD2 63/4885ADRA1A 207/4885 |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | HTR1A 16/4885DRD2 8/4885ADRA1A 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.